Knockdown of RAGE expression inhibits colorectal cancer cell invasion and suppresses angiogenesis in vitro and in vivo

Cancer Letters

Volumn 313, Issue 1, 2011, Pages 91-98

  Liang, Huasheng ^a   Zhong, Yuhua ^a   Zhou, Shaobi ^a   Peng, Liang ^b  

^a Beihai Institute of Endocrine and Metabolic Diseases   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Colorectal cancer; RAGE; VEGF

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; MESSENGER RNA; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; SHORT HAIRPIN RNA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER TISSUE; CELL INTERACTION; CELL INVASION; CELL VIABILITY; CHICK; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; SP1 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80054090526     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.08.028     Document Type: Article

References (25)

1. Bierhaus A., Nawroth P.P. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, Immune responses and diabetes mellitus and its complications. Diabetologia 2009, 52:2251-2263.
2. Cho S.G., Yi Z., Pang X., Yi T., Wang Y., Luo J., Wu Z., Li D., Liu M. Kisspeptin-10, a KISS1-derived decapeptide, inhibits tumor angiogenesis by suppressing Sp1-mediated VEGF expression and FAK/Rho GTPase activation. Cancer Res. 2009, 69:7062-7070.
3. Li J., Schmidt A.M. Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J. Biol. Chem. 1997, 272:16498-16506.
4. Kuhla B., Loske C., Garcia De Arriba S., Schinzel R., Huber J., Munch G. Differential effects of "Advanced glycation endproducts" and beta-amyloid peptide on glucose utilization and ATP levels in the neuronal cell line SH-SY5Y. J. Neural. Transm. 2004, 111:427-439.
5. Turovskaya O., Foell D., Sinha P., Vogl T., Newlin R., Nayak J., Nguyen M., Olsson A., Nawroth P.P., Bierhaus A., Varki N., Kronenberg M., Freeze H.H., Srikrishna G. RAGE carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008, 29:2035-2043.
6. Fuentes M.K., Nigavekar S.S., Arumugam T., Logsdon C.D., Schmidt A.M., Park J.C., Huang E.H. RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways. Dis. Colon. Rectum. 2007, 50:1230-1240.
7. Bierhaus A., Schiekofer S., Schwaninger M., Andrassy M., Humpert P.M., Chen J., Hong M., Luther T., Henle T., Kloting I., Morcos M., Hofmann M., Tritschler H., Weigle B., Kasper M., Smith M., Perry G., Schmidt A.M., Stern D.M., Haring H.U., Schleicher E., Nawroth P.P. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappa B. Diabetes 2001, 50:2792-2808.
8. Taguchi A., Blood D.C., del Toro G., Canet A., Lee D.C., Qu W., Tanji N., Lu Y., Lalla E., Fu C., Hofmann M.A., Kislinger T., Ingram M., Lu A., Tanaka H., Hori O., Ogawa S., Stern D.M., Schmidt A.M. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000, 405:354-360.
9. Kuniyasu H., Chihara Y., Kondo H. Differential effects between amphoterin and advanced glycation end products on colon cancer cells. Int. J. Cancer 2003, 104:722-727.
10. Kuniyasu H., Chihara Y., Kondo H., Ohmori H., Ukai R. Amphoterin induction in prostatic stromal cells by androgen deprivation is associated with metastatic prostate cancer. Oncol. Rep. 2003, 10:1863-1868.
11. Kuniyasu H., Chihara Y., Takahashi T. Co-expression of receptor for advanced glycation end products and the ligand amphoterin associates closely with metastasis of colorectal cancer. Oncol. Rep. 2003, 10:445-448.
12. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005, 69:4-10.
13. de la Torre N.G., Turner H.E., Wass J.A. Angiogenesis in prolactinomas: regulation and relationship with tumour behavior. Pituitary 2005, 8:17-23.
14. Shen H.L., Xu W.L., Wu Z.Y., Qi Y.Y., Zhong X.M., Huang W.B., Xiao M. Inhibition of vascular endothelial growth factor gene expression and proliferation of leukemia cells by RNA interference. Zhonghua Xue Ye Xue Za Zhi 2005, 26:710-714.
15. Barr M.P., Bouchier-Hayes D.J., Harmey J.J. Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia. Int. J. Oncol. 2008, 32:41-48.
16. Gordon M.S., Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology 2005, 69:25-33.
17. Finkenzeller G., Sparacio A., Technau A., Marme D., Siemeister G. Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Oncogene 1997, 15:669-676.
18. Yi T., Yi Z., Cho S.G., Luo J., Pandey M.K., Aggarwal B.B., Liu M. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res. 2008, 68:1843-1850.
19. Weitz J., Koch M., Debus J., Hohler T., Galle P.R., Buchler M.W. Colorectal cancer. Lancet 2005, 365:153-165.
20. Li J., Saif M.W. Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. Biologics 2009, 3:429-441.
21. Abe R., Fujita Y., Yamagishi S. Angiogenesis and metastasis inhibitors for the treatment of malignant melanoma. Mini. Rev. Med. Chem. 2007, 7:649-661.
22. Varker K.A., Biber J.E., Kefauver C., Jensen R., Lehman A., Young D., Wu H., Lesinski G.B., Kendra K., Chen H.X., Walker M.J., Carson W.E. 3rd A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann. Surg. Oncol. 2007, 14:2367-2376.
23. Csiszar A., Ungvari Z. Endothelial dysfunction and vascular inflammation in type 2 diabetes: interaction of AGE/RAGE and TNF-alpha signaling. Am. J. Physiol. Heart Circ. Physiol. 2008, 295:H475-476.
24. Pradeep C.R., Sunila E.S., Kuttan G. Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies. Integr. Cancer Ther. 2005, 4:315-321.
25. Abdelrahim M., Smith R., Burghardt R., Safe S. Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells. Cancer Res. 2004, 64:6740-6749.